280 related articles for article (PubMed ID: 23640346)
1. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
2. New agents for the management of castration-resistant prostate cancer.
Cersosimo RJ
Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
[TBL] [Abstract][Full Text] [Related]
3. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
4. New treatment options for patients with metastatic castration-resistant prostate cancer.
Higano CS
Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O; Michels RM; Massard C; de Bono JS
Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
8. New agents in the arsenal to fight castrate-resistant prostate cancer.
Ezzell EE; Chang KS; George BJ
Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
[TBL] [Abstract][Full Text] [Related]
9. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Ouzaid I; Ravery V; Pouessel D; Culine S
Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
[TBL] [Abstract][Full Text] [Related]
10. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
Gravanis I; Lopez AS; Hemmings RJ; Jiménez JC; Garcia-Carbonero R; Gallego IG; Giménez EV; O'Connor D; Giuliani R; Salmonson T; Pignatti F
Oncologist; 2013; 18(9):1032-42. PubMed ID: 23966222
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
[TBL] [Abstract][Full Text] [Related]
12. Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC; Smaletz O; Herchenhorn D
Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
[TBL] [Abstract][Full Text] [Related]
13. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Pal SK; Sartor O
Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995
[TBL] [Abstract][Full Text] [Related]
14. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
15. [Second line therapy for castration-resistant prostate cancer (CRPC)].
Molitor B; Börgermann C
Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
[TBL] [Abstract][Full Text] [Related]
16. A new era for castrate resistant prostate cancer: a treatment review and update.
Fong MK; Hare R; Jarkowski A
J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
[TBL] [Abstract][Full Text] [Related]
17. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
18. Contemporary management of metastatic castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
20. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
